- Stocks
- Healthcare
- NASDAQ: CODX

Price (delayed)

$3.86

Market cap

$130.39M

P/E Ratio

4.15

Dividend/share

N/A

EPS

$0.93

Enterprise value

$44.84M

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using

The stock's price to earnings (P/E) is 32% less than its last 4 quarters average of 6.1

The company's debt fell by 12% QoQ

Co-Diagnostics's quick ratio has surged by 76% QoQ but it has decreased by 10% YoY

The equity has surged by 66% year-on-year but it has declined by 2.2% since the previous quarter

CODX's EPS is down by 43% year-on-year and by 31% since the previous quarter

CODX's net income is down by 39% year-on-year and by 31% since the previous quarter

What are the main financial stats of CODX

Market
Valuations
Earnings

Shares outstanding

33.78M

Market cap

$130.39M

Enterprise value

$44.84M

Price to earnings (P/E)

4.15

Price to book (P/B)

0.91

Price to sales (P/S)

1.6

EV/EBIT

1.34

EV/EBITDA

1.3

EV/Sales

0.57

Revenue

$78.22M

EBIT

$33.49M

EBITDA

$34.38M

Free cash flow

$24.66M

Per share
Balance sheet
Liquidity

EPS

$0.93

Free cash flow per share

$0.76

Book value per share

$4.25

Revenue per share

$2.41

TBVPS

$3.65

Total assets

$160.84M

Total liabilities

$16.37M

Debt

$489,166

Equity

$144.47M

Working capital

$107.85M

Debt to equity

0

Current ratio

17.06

Quick ratio

16.12

Net debt/EBITDA

-2.49

Margins
Efficiency
Dividend

EBITDA margin

43.9%

Gross margin

87.2%

Net margin

35.8%

Operating margin

37.9%

Return on assets

18.8%

Return on equity

21.3%

Return on invested capital

165.2%

Return on capital employed

21.7%

Return on sales

42.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Co-Diagnostics stock price performed over time

Intraday

-6.08%

1 week

-41.69%

1 month

-33.22%

1 year

-65.04%

YTD

-56.77%

QTD

-31.19%

How have Co-Diagnostics's revenue and profit performed over time

Revenue

$78.22M

Gross profit

$68.23M

Operating income

$29.62M

Net income

$28M

Gross margin

87.2%

Net margin

35.8%

CODX's operating income is down by 41% YoY and by 35% from the previous quarter

CODX's net income is down by 39% year-on-year and by 31% since the previous quarter

Co-Diagnostics's operating margin has decreased by 27% YoY and by 16% from the previous quarter

The company's net margin fell by 25% YoY and by 11% QoQ

What is Co-Diagnostics's growth rate over time

What is Co-Diagnostics stock price valuation

P/E

4.15

P/B

0.91

P/S

1.6

EV/EBIT

1.34

EV/EBITDA

1.3

EV/Sales

0.57

CODX's EPS is down by 43% year-on-year and by 31% since the previous quarter

The stock's price to earnings (P/E) is 32% less than its last 4 quarters average of 6.1

The P/B is 96% below the 5-year quarterly average of 20.9 and 52% below the last 4 quarters average of 1.9

The equity has surged by 66% year-on-year but it has declined by 2.2% since the previous quarter

The P/S is 100% below the 5-year quarterly average of 1214.9 and 33% below the last 4 quarters average of 2.4

The revenue has contracted by 22% from the previous quarter and by 19% YoY

How efficient is Co-Diagnostics business performance

The ROA has plunged by 70% YoY and by 39% from the previous quarter

CODX's return on equity has dropped by 67% year-on-year and by 38% since the previous quarter

CODX's return on invested capital is down by 39% since the previous quarter and by 24% year-on-year

CODX's return on sales is down by 18% year-on-year and by 12% since the previous quarter

What is CODX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CODX.

How did Co-Diagnostics financials performed over time

Co-Diagnostics's total liabilities has soared by 196% YoY but it has decreased by 30% from the previous quarter

The current ratio has soared by 77% from the previous quarter but it has decreased by 11% YoY

The company's debt is 100% lower than its equity

The equity has surged by 66% year-on-year but it has declined by 2.2% since the previous quarter

The company's debt fell by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.